CD8A and neoplasm: Functionally, ALKBH5 activity can impact CD8+ T cell infiltration and cytotoxicity, the recruitment of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophage (TAM) subsets, as well as dendritic cell antigen presentation capacity, ultimately influencing the efficacy of immune checkpoint inhibitors (ICIs) and other anti-cancer immunotherapies (19).